A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Clinical trial NCT06040099 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06040099
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-13
- Primary completion
- 2026-07-01
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.